Yuwei Wang

Key Laboratory Of Shaanxi Administration Of Traditional Chinese Medicine For TCM Compatibility
Xianyang, 712046, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Disarming cGAS-STING hyperactivation in autoimmune and inflammatory diseases: Pathogenic mechanisms and emerging therapeutic strategies.

Disarming cGAS-STING hyperactivation in autoimmune and inflammatory diseases: Pathogenic mechanisms and emerging therapeutic strategies.

Journal: Pharmacological research

Published: June 01, 2026

Identification and structure-activity relationship optimization of dibromoacetophenones as novel mIDH1 inhibitors.

Identification and structure-activity relationship optimization of dibromoacetophenones as novel mIDH1 inhibitors.

Journal: European journal of medicinal chemistry

Published: May 17, 2025

Selective JAK1 inhibitors and the therapeutic applications thereof: a patent review (2016-2023).

Selective JAK1 inhibitors and the therapeutic applications thereof: a patent review (2016-2023).

Journal: Expert opinion on therapeutic patents

Published: December 24, 2024

TRP channels in cancer: Therapeutic opportunities and research strategies.

TRP channels in cancer: Therapeutic opportunities and research strategies.

Journal: Pharmacological research

Published: July 08, 2024

Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors.

Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors.

Journal: Journal of medicinal chemistry

Published: June 24, 2024

Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML.

Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML.

Journal: European journal of medicinal chemistry

Published: March 07, 2024

Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia.

Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia.

Journal: European journal of medicinal chemistry

Published: August 09, 2023

Erratum: Author correction to 'Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling' [Acta Pharmaceutica Sinica B 12 (2022) 1198-1212].

Erratum: Author correction to 'Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling' [Acta Pharmaceutica Sinica B 12 (2022) 1198-1212].

Journal: Acta pharmaceutica Sinica. B

Published: July 22, 2022

Recent advances of IDH1 mutant inhibitor in cancer therapy.

Recent advances of IDH1 mutant inhibitor in cancer therapy.

Journal: Frontiers in pharmacology

Published: June 30, 2022

Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling.

Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling.

Journal: Acta pharmaceutica Sinica. B

Published: July 29, 2021

Layered terbium hydroxides for simultaneous drug delivery and imaging.

Layered terbium hydroxides for simultaneous drug delivery and imaging.

Journal: Dalton transactions (Cambridge, England : 2003)

Published: July 13, 2021

Curcumin sensitizes prostate cancer cells to radiation partly via epigenetic activation of miR-143 and miR-143 mediated autophagy inhibition.

Curcumin sensitizes prostate cancer cells to radiation partly via epigenetic activation of miR-143 and miR-143 mediated autophagy inhibition.

Journal: Journal of drug targeting

Published: April 11, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026